Namdev N Shinde¹*, Divya G Thite², Sameer Sawant³, Gauri R Patil¹, Dipak S Nandurkar⁴, Vishnu S Doltade⁵, Sakshi Datir¹ and Vishvas U Shinde¹

¹Student of Sinhgad College of Pharmacy, Pune, India
²Assistant Professor of Sinhgad College of Pharmacy, Pune, India
³Associate Professor of Sinhgad College of Pharmacy, narhe, Pune, India
⁴Central University of Rajasthan, India
⁵Asian College of Science and Commerce, India

*Corresponding Author: Namdev Niloba Shinde, Student of Sinhgad College of pharmacy, Pune, India.

Received: January 16, 2025; Published: January 30, 2025

Abstract

Alzheimer’s disease is the most common neurodegenerative disorder in the central nervous system. As Herbal medicines are mainly used as a complementary and alternative therapy. This study aimed at investigating the potential therapeutic effects, poten tial Alzheimer associated targets, and underlying molecular mechanisms of Formononetin in the treatment of Alzheimer’s disease. Puerarin-associated potential targets, and metabolic pathways involved in Puerarin disease were explored through systemic biology based network pharmacology assay and molecular docking Chemo informative tools and databases i.e. DIGEP-Pred and DisGeNET were used. Further, STRING was used to enrich the protein-protein interaction for the bioactive modulated targets. Similarly, mo lecular docking was performed using AutoDock Vina. In the following network pharmacology assay, bioactives in camellia sinesis were identified based on druglike characteristics, and pharmacokinetics profiles. Moreover, forty-four molecular targets and fifteen biochemical pathways were uncovered through molecular docking. TNF, AKT1, EGFR, TP53, APTGS2, BCL2, PPARG, ESR1 ,HIF1A and MMP9 are implicated in the inhibition of Alzheimer’s symptoms through modulating the cAMP signaling pathway, calcium signal ing pathway, GABAergic and dopaminergic synaptic activities, pathway. In terms of safety, efficacy, and sustainability, the one-drug/ one-target/one-disease approach to drug discovery is currently experiencing numerous difficulties. Recently, network biology and polypharmacology approaches have become more popular as methodologies for multitarget drug development and omics data inte gration, respectively. These two methods were combined to produce a brand-new paradigm known as network pharmacology (NP), which examines how medications affect both the interactome and the diseasome level.

Keywords: Alzheimer’s Disease; Isoflavonoids; Puerarin; Network Pharmacology; Molecular Docking

References

1. Scheltens P., et al. “Alzheimer’s disease”. The Lancet10043 (2016): 505-517.
2. Chandran U., et al. “Network pharmacology”. Innovative Approaches in Drug Discovery (2017): 127.
3. Masters CL., et al. “Alzheimer’s disease”. Nature Reviews Disease Primers 1 (2015): 15056.
4. Chaudhary RK., et al. “Anti-diabeti potential of corn silk (Stigma maydis): an in-silico approach”. Journal of Diabetes and Metabolic Disorders1 (2022): 445-454.
5. Chen L., et al. “Network pharmacology-based strategy for predicting active ingredients and potential targets of Yangxinshi tablet for treating heart failure”. Journal of Ethnopharmacology 219 (2018): 359-368.
6. DeTure MA and Dickson DW. “The neuropathological diagnosis of Alzheimer’s disease”. Neurodegener 14 (2019):1-18.
7. Gai J., et al. “Exploration of potential targets and mechanisms of Naringenin in treating autism spectrum disorder via network pharmacology and molecular docking”. Medicine 46 (2022).
8. Hewlings SJ and Kalman DS. “Curcumin: a review of its' effects on human health”. Foods10 (2017): 92.
9. Hopkins AL. “Network pharmacology: the next paradigm in drug discovery”. Nat Chem Biol 11 (2008): 682-690.
10. Huminiecki L., et al. “The functional genomic studies of curcumin”. Semin Cancer Biol 46 (2017): 107-118.
11. Soria Lopez JA., et al. “Alzheimer’s disease”. Handbook of Clinical Neurology (2019): 231-255.
12. Lanctôt KL., et al. “Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms”. Alzheimer’s and Dementia: Translational Research and Clinical Interventions 3 (2017): 440-449.
13. Belinky F., et al. “Non-redundant compendium of human ncRNA genes in GeneCards”. Bioinformatics2 (2013): 255-261.
14. Bibl M., et al. “CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia”. Brain 5 (2006): 1177-1187.
15. Burns A and Iliffe S. “Alzheimer’s disease”. BMJ (Online) 7692 (2009): 467-471.
16. Claeysen S., et al. “Alzheimer culprits: Cellular crossroads and interplay”. Cellular Signalling 24.9 (2012): 1831-1840.
17. Eftekharzadeh B., et al. “Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease”. Neuron 5 (2018): 925-940.e7.
18. Gao X., et al. “A Network Pharmacology Approach to Estimate Potential Targets of the Active Ingredients of Epimedium for Alleviating Mild Cognitive Impairment and Treating Alzheimer’s Disease”. Evidence-Based Complementary and Alternative Medicine (2021).
19. Gfeller D., et al. “Swiss Target Prediction: a web server for target prediction of bioactive small molecules”. Nucleic Acids Research 42 (2014): 32-38.
20. Lane CA. “Alzheimer’s disease”. European Journal of Neurology (2018): 59-70.
21. Long JM and Holtzman DM. “Alzheimer Disease: An Update on Pathobiology and Treatment Strategies”. Cell 2 (2019): 312-339.
22. Maccioni RB., et al. “Pathway to Tau Modifications and the Origins of Alzheimer’s Disease”. Archives of Medical Research2 (2018): 130-131.
23. Noor F., et al. “Network Pharmacology Approach for Medicinal Plants: Review and Assessment”. Pharmaceuticals (Basel) (2022): 1-
24. O’Brien RJ and Wong PC. “Amyloid precursor protein processing and alzheimer’s disease”. Annual Review of Neuroscience 34 (2011): 185-204.
25. Shannon P., et al. “Cytoscape: A software Environment for integrated models of biomolecular interaction networks”. Genome Research11 (2003): 2498-2504.
26. Szklarczyk D., et al. “STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets”. Nucleic Acids ResearchD1 (2019): D607-D613.
27. Yin H., et al. “Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer”. BioMed Research International (2016).
28. Zhang YW., et al. “APP processing in Alzheimer’s disease”. Molecular Brain1 (2011): 1-13.

Citation

Citation: Namdev N Shinde. “Exploring the Neuroprotective Potential of Puerarin in Alzheimer’s Diseases: ‘A Network Pharmacology and Molecular Docking Approach’" Acta Scientific Pharmaceutical Sciences 9.2 (2025): 47-55.

Copyright

Copyright: © 2025 Namdev N Shinde. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.